Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Combination of dasatinib and quercetin promotes osteogenic differentiation and stemness maintenance of hPDLSCs via YAP/TAZ

Qiu Y., Zhao Y., Jia L., Xiao H., Sun S., Gu W.

Laboratory Study on Ligament Injury, published in Anim Cells Syst (Seoul) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Anim Cells Syst (Seoul) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40098711
PMCID
PMC11912249
DOI
10.1080/19768354.2025.2477050
Citations
4

Abstract (original English)

Human periodontal ligament stem cells (hPDLSCs) are candidate seed cells for periodontal tissue regeneration. Enhancing the stemness maintenance and osteogenic differentiation potential of hPDLSCs is conducive to their role in periodontal tissue regeneration. The combination of dasatinib and quercetin, a type of senolytic, has been reported to affect cell senescence. However, whether it can regulate the osteogenic differentiation and stemness maintenance of hPDLSCs, and the related mechanisms, remain unknown. The present study analyzed the optimal concentrations of dasatinib and quercetin in combination for hPDLSCs and found that the combination of dasatinib and quercetin enhanced osteogenic differentiation and promoted the expression of stemness-related markers in hPDLSCs. The expression levels of TAZ and YAP were improved when hPDLSCs were incubated with dasatinib and quercetin. However, the osteogenesis-promoting effects of dasatinib plus quercetin were partly attenuated when TAZ was knocked down, and their effects on stemness-related markers were suppressed when YAP was inhibited. Taken together, the combination of dasatinib and quercetin promotes the osteogenic differentiation and stemness maintenance of hPDLSCs, and YAP/TAZ may be involved in this process. This combination may hold promise for improving hPDLSCs function in periodontal tissue regeneration.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research